Labopharm (DDSS): The 52-Week Low Club
Labopharm (DDSS) Drug being delayed by FDA review. Stock down by more than half to 52-week low of $2.83 from 52-week high of $9.07. Point Therapeutics (POTP) After putting drug trial on hold, cuts 60% of workforce. Drops to $.10…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Labopharm (DDSS) Drug being delayed by FDA review. Stock down by more than half to 52-week low of $2.83 from 52-week high of $9.07.
Point Therapeutics (POTP) After putting drug trial on hold, cuts 60% of workforce. Drops to $.10 from 52-week high of $3.01.
Spatialight (HDTV) Maker of liquid crystal microdisplays used in high-definition keeps falling after poor quarterly results. Down to $.10 from 52-week high of $3.10.
Headwaters (HW) Provides products to energy and construction industries. Debate over coal-to-fuel programs, including companies that HW supplies hurt stock price. Down to $19.10 from 52-week high of $27.81.
Douglas A. McIntyre
Contact [email protected] for any questions or corrections.



